Subham Basu Email & Phone Number

Uppsala, Uppsala County, Se

Leading sales, marketing, business development and strategy for innovative spatial biology company.

Cambridge, Cambridgeshire, Gb

• Continuing to lead on Immuno-oncology and Oncology strategy with greater focus on external engagement via corporate and business development• Direct launch of individual and classes of assets for Immuno-oncology and Oncology• Establish and develop Oncology Research Area, developing in-house talent and building out portfolio and directing commercial strategy• Scouting and leading on partnering with pharma, biotechnology, and academic research centers, working with business development and corporate development teams to expand company portfolio and ensure Abcam assets have maximum exposure in market

Cambridge, Cambridgeshire, Gb

Develop and direct commercial strategy for immuno-oncology portfolio for Abcam, working cross-functionally with marketing, sales, product development and validation, research and business development teams. Vision is to ensure that all researchers ( working across fundamental research, drug discovery, translational medicine and clinical science and across academia, biotech/ pharma and diagnostics/platforms) can access the best tools and solutions for their immuno-oncology advancements for identifying, selecting and treating patients for optimal care.

I am a clinical and biomedical sciences expert, with an oncology and platform technology focus. Prior to joining IPBA, I served as Global Medical Affairs Diagnostics Lead for AZ’s DNA Damage franchise, working with commercial, medical, clinical and pre-clinical teams, and in collaboration with Merck to lead Dx strategies in ovarian, breast, prostate and pancreatic cancers. I have over 7 years experience working with UK, European and Global teams in oncology with Shire/Baxlata, Otsuka/BMS and Genzyme in implementing brand strategies for pre-marketed and just-launched marketed assets in oncology and hematology. I have also worked deeply within market access/HEOR and has been UK lead on HTA presentations to NICE. I conduct due diligence and scouting for leads for pharma venture capital and BD. Previous to industry, I have prior experience in directing a competitive research laboratory in academia and therefore have hands-on leadership in pre-clinical work to marketing of drugs.

Clinical and biomedical sciences expert, with an oncology and platform technology focus, currently working in strategy consulting and venture capital+8 years in pharmaceutical industry in diagnostics, medical affairsExtensive prior experience in leading a competitive research laboratory in academiaPhD, Molecular Pharmacology, Cornell University/Memorial Sloan Kettering Cancer Center

Cambridge, Cambridgeshire, Gb

Tokyo, Jp, Jp

• Led scientific/clinical due diligence for go/no-go decisions to expand Baxter/Baxalta Venture Capital portfolio as well as scouting for new leads in US and Europe which were actively pursued • Consulting on Business Development leads.• Cross-functional engagement with Medical, Market Access, Health Economy Outcomes Research (HEOR), Clinical Development and Marketing teams across Europe and Globally to launch Oncaspar (pegylated aspariginase) in acute lymphoblastic leukaemia (ALL) and Onivyde (liposomal irinotecan) in pancreatic cancer as first oncology assets developed by Baxalta/Shire in UK and Europe.• Successfully obtained positive National Institute of Clinical and Care Excellence (NICE) and Scottish Medical Council (SMC) Health Technology Assessment (HTA) approvals in UK for Oncaspar in ALL.• Led Global projects to generate educational and promotional materials for training, congress programmes and speaker development.• Directed Medical Affairs, Market Access, HEOR and Marketing Advisory Boards in UK and Europe.• Developed and implemented medical plan and budget for oncology assets in UK and Ireland.• Experience with directing various agencies for external help in generating materials, developing HTA dossiers, coordinating advisory boards and educational programmes

Illinois, Us

I am the country-wide lead for medical and clinical strategy for oncology products and services, including pre-launch planning, trial support and KOL development. I work across departments, including Market Access, Patient Access, Marketing and with Global and European colleagues to help generate and deliver the oncology medical affairs plan for UK and Ireland.

Illinois, Us

Medical and clinical strategy for oncology products and services, including pre-launch planning, trial support and KOL development. I work across departments, including Market Access, Patient Access, Marketing and with Global and European colleagues to help generate and deliver the oncology medical affairs plan for UK and Ireland.

Deerfield, Illinois, Us

Medical and clinical strategy for investigational and licensed oncology products and services, including pre-launch and trial planning and support and KOL development.

Medical support for marketed products and investigational products, including:Key Opinion Leader development and management.Presenting clinical data and participation in advisory meetings.Clinical development support (investigator supported studies, etc)Medical and strategy planning.

Contracted to advise and assist on clinical research, focusing on investigator supported studies.

• Strong publication record in high impact journals including demonstrating regulation of key signaling molecules in cancer.• Successfully supervised 5 postdoctoral fellows and 3 PhD students, who have gone to top-flight academic postdoctoral fellowships in world class institutions such as MIT as well as Senior Project Executive posts in leading medical publishing firms.• Secured competitive grant money equivalent to over $1.5 million from Cancer Research UK and Barts and the London Trust charities.• Effective communicator and writer, with published reviews in high profile journal such as Molecular Cell, Cell Death and Differentiation, Oncogene and Cell Cycle. Presented invited seminars at international conferences and leading research institutes and universities.

London, Gb

• Discovered detailed mechanisms of tumorigenesis and chemoresistance for druggable targets including Raf, Akt, JNK, Abl kinases and p53 family members and others using a range of cutting edge in vitro techniques including functional proteomic screens and in vivo assays in cell culture and mice.• Designed, developed and characterized new, innovative reagents such as phospho-specific antibodies, cells lines stably expressing mutant constructs and advised on transgenic animals.

London, Gb

Worked in Signal Transduction Laboratory in identifying and characterizing substrates of Akt involved in tumorigenesis.

Established Cell Survival Signalling Laboratory in CRUK Molecular Oncology Unit.

New York, Ny, Us

• Characterized the effect of the bioactive lipid ceramide in signaling apoptosis through activation of Ras and Raf-1 and inactivation of Ak

Mergers & Acquisitions Program

Phd, Molecular Pharmacology

Ba, Neuroscience Field Major

Education record